SAB Biotherapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $114 | $ |
Gross Profit | -822 | -778 | -671 | -1,000 |
EBITDA | -9,732 | -4,349 | -10,538 | -9,305 |
EBIT | -10,554 | -5,127 | -11,323 | -10,271 |
Net Income | -10,114 | -5,197 | -11,395 | -10,349 |
Net Change In Cash | 0 | 0 | 114 | |
Free Cash Flow | -14,484 | -7,797 | -9,587 | -6,392 |
Cash | 3,692 | 5,640 | 8,897 | 9,171 |
Basic Shares | 9,294 | 9,292 | 9,262 | 9,259 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $1,322 | $2,239 | $23,904 | $60,876 |
Gross Profit | -3,470 | -1,506 | 20,612 | 59,222 |
EBITDA | -28,994 | -38,133 | -15,122 | -15,196 |
EBIT | -33,787 | -41,878 | -18,414 | -16,850 |
Net Income | -34,105 | -42,194 | -18,741 | -17,145 |
Net Change In Cash | 1,322 | 2,239 | 23,904 | 60,876 |
Free Cash Flow | -34,629 | -25,316 | -7,185 | -7,185 |
Cash | 8,897 | 56,566 | 15,046 | 33,206 |
Basic Shares | 9,262 | 5,521 | 4,352 | 2,734 |
Earnings Calls
| Quarter | EPS |
|---|---|
2021-06-30 | -$0.12 |
2021-03-31 | -$0.02 |
2020-12-31 | -$0.02 |
2020-09-30 | $0.15 |
